

Continuing Medical Education (CME) Questions

Efficacy and safety of 2-CdA for mastocytosis

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to <http://www.medscape.org/journal/blood>. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers. You must be a registered user on <http://www.medscape.org>. If you are not registered on <http://www.medscape.org>, please click on the “Register” link on the right hand side of the website. Only one answer is correct for each question. Once you successfully answer all post-test questions you will be able to view and/or print your certificate. For questions regarding the content of this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@webmd.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please refer to <http://www.ama-assn.org/ama/pub/about-ama/awards/ama-physicians-recognition-award.page>. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for *AMA PRA Category 1 Credits™*. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C, Hamidou M, Durieu I, Suarez F, Grosbois B, Limal N, Gyan E, Larroche C, Guillet G, Kahn JE, Casassus P, Amazzough K, Coignard-Biehler H, Georgin-Lavialle S, Lhermitte L, Fraitag S, Canioni D, Dubreuil P, Hermine O. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. *Blood*. 2015;126(8):1009-1016.

1. Your patient is a 56-year-old woman with indolent mastocytosis. According to the clinical case series by Barete and colleagues, which of the following statements about the efficacy of cladribine (2-chlorodeoxyadenosine [2-CdA]) in indolent disease is correct?

- One-quarter of patients had a complete response to treatment
- One-quarter of patients had a major response to treatment
- Median duration of response was 1 year
- Patients with indolent or advanced mastocytosis had clinical improvement in 10 of 11 mediator release symptoms (such as fatigue, flush, pruritus, diarrhea, or abdominal pain)

2. According to the clinical case series by Barete and colleagues, which of the following statements about the efficacy of 2-CdA in advanced mastocytosis is correct?

- Among patients with indolent or advanced disease, there were improvements in 6 of 7 mast cell infiltration–related symptoms (such as urticaria pigmentosa, hepatomegaly, and splenomegaly)
- Three-quarters of patients with advanced disease had a major or partial response
- Median duration of response for aggressive disease was 18 months
- Serum tryptase levels did not change significantly among patients with indolent or aggressive disease

3. According to the clinical case series by Barete and colleagues, which of the following statements about the toxicity of 2-CdA in patients with mastocytosis is correct?

- Clinical tolerance of 2-CdA treatment was poor in most of the patients
- The most frequent grade 3/4 toxicities were lymphopenia (82%), neutropenia (47%), and opportunistic infections (13%)
- Suspected or confirmed infectious complications during 2-CdA administration occurred in nearly half of patients
- Two patients with indolent mastocytosis died of toxicity related to 2-CdA

Activity Evaluation (where 1 is strongly disagree and 5 is strongly agree)

1. The activity supported the learning objectives.

1	2	3	4	5
---	---	---	---	---
2. The material was organized clearly for learning to occur.

1	2	3	4	5
---	---	---	---	---
3. The content learned from this activity will impact my practice.

1	2	3	4	5
---	---	---	---	---
4. The activity was presented objectively and free of commercial bias.

1	2	3	4	5
---	---	---	---	---